CD274 and head and neck squamous cell carcinoma: In the era of emerging immunotherapy, APIs may be considered an alternative therapy in HNSCC, which could improve the OS, OS in patients with >1% PD-L1 expression, and DOR, as well as with a better safety profile as compared to chemotherapy and combination ICI.